

EMA/915926/2022

European Medicines Agency decision P/0520/2022

of 30 December 2022

on the agreement of a paediatric investigation plan and on the granting of a deferral for stiripentol (EMA-003200-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0520/2022

of 30 December 2022

on the agreement of a paediatric investigation plan and on the granting of a deferral for stiripentol (EMA-003200-PIP01-22) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Biocodex SA on 21 February 2022 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 11 November 2022, in accordance with Article 17 of Regulation (EC) No 1901/2006 and Article 21 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral.
- (2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.
- (3) It is therefore appropriate to adopt a decision granting a deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A paediatric investigation plan for stiripentol, capsule, hard, powder for oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

Article 2

A deferral for stiripentol, capsule, hard, powder for oral suspension, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 3

This decision is addressed to Biocodex SA, 7 avenue Gallieni, 94257 - Gentilly Cedex, France.

EMA/PDCO/686120/2022
Amsterdam, 11 November 2022

Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral

EMA-003200-PIP01-22

Scope of the application

Active substance(s):

Stiripentol

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of primary hyperoxaluria

Pharmaceutical form(s):

Capsule, hard

Powder for oral suspension

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Biocodex SA

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, Biocodex SA submitted for agreement to the European Medicines Agency on 21 February 2022 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation.

The procedure started on 21 March 2022.

Supplementary information was provided by the applicant on 8 August 2022. The applicant proposed modifications to the paediatric investigation plan.

Opinion

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

- to agree the paediatric investigation plan in accordance with Article 17(1) of said Regulation;
- to grant a deferral in accordance with Article 21 of said Regulation.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable

2. Paediatric investigation plan

2.1. Condition:

Treatment of primary hyperoxaluria

2.1.1. Indication(s) targeted by the PIP

Treatment of primary hyperoxaluria

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

Powder for oral suspension

2.1.4. Measures

Area	Description
Quality-related studies	Not applicable
Non-clinical studies	Not applicable
Clinical studies	Study 1: Open-label, non-comparative trial to evaluate efficacy and safety of stiripentol in paediatric patients from 6 months to less than 18 years of age (and adults) with primary hyperoxaluria (type 1, 2, or 3) and relatively preserved renal function. (STP194; HYPOP) Study 2: Double-blind, randomised, placebo-controlled trial to evaluate efficacy, safety and pharmacokinetics of stiripentol in paediatric patients from 6 years to less than 18 years of age (and adults) with primary hyperoxaluria (type 1, 2 or 3) with potential mild and moderate renal impairment. (STP226; CRYSTAL) Study 3: Open-label, non-comparative trial to evaluate efficacy and safety of stiripentol in paediatric patients from birth to less than 6 years of age with primary hyperoxaluria (type 1, 2 or 3) and relatively preserved renal function. (STP239)

Modelling and simulation studies	Study 4: Modelling and simulation study to evaluate the use of stiripentol in the treatment of primary hyperoxaluria in children from birth to less than 18 years of age. (STP238)
Other studies	Not applicable
Extrapolation plan	Study 1, Study 2, Study 3 and Study 4 are part of an extrapolation plan covering the paediatric population from birth to less than 18 years of age, as agreed by the PDCO.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By December 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.